SEC filings

mPhase Technologies Inc. Announces $3 Million Financing

Tuesday, May 11, 2021 - 1:31pm

The note matures on May 5, 2022 and bears interest at the rate of 5% per annum.

Key Points: 
  • The note matures on May 5, 2022 and bears interest at the rate of 5% per annum.
  • The note was specifically crafted so that it should not, in our view, impede a future listing to a national securities exchange.
  • The Company is assembling industry-leading teams specializing in artificial intelligence, machine learning, software, consumer engagement, and other advanced technologies.
  • Forward-looking statements also are affected by the risk factors described in the Company\xe2\x80\x99s filings with the U.S. Securities and Exchange Commission.

Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences

Tuesday, May 11, 2021 - 1:05pm

Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform.\nLenabasum is not approved for the treatment of any indication.

Key Points: 
  • Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform.\nLenabasum is not approved for the treatment of any indication.
  • Such factors include those set forth in the Company\'s filings with the Securities and Exchange Commission.
  • Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.\n'

Xtant Medical Files $150 Million Shelf Registration Statement

Tuesday, May 11, 2021 - 12:00pm

b'BELGRADE, Mont., May 11, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today it has filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC).

Key Points: 
  • b'BELGRADE, Mont., May 11, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today it has filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC).
  • Under the shelf registration, upon being declared effective by the SEC, Xtant may offer and sell, from time to time over a three-year period, various securities in an amount of up to $150 million.
  • In addition, the registration statement, upon effectiveness, will allow certain stockholders affiliated with OrbiMed Advisors, LLC to offer and sell, from time to time, up to 18,218,374 shares of Xtant common stock.\nThe shelf registration statement is intended to afford Xtant the flexibility to finance future growth initiatives and business opportunities by accessing the capital markets on a timely and cost-effective basis.
  • At the present time, the Company has no specific plans to issue securities under the registration statement.

argenx announces results of Annual General Meeting of Shareholders

Tuesday, May 11, 2021 - 10:00am

A further list and description of these risks, uncertainties and other risks can be found in\xc2\xa0argenx\xe2\x80\x99s\xc2\xa0U.S.

Key Points: 
  • A further list and description of these risks, uncertainties and other risks can be found in\xc2\xa0argenx\xe2\x80\x99s\xc2\xa0U.S.
  • Securities and Exchange Commission (SEC) filings and reports, including in\xc2\xa0argenx\xe2\x80\x99s\xc2\xa0most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC.
  • Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.
  • argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.\n'

Stable Road Reminds Stockholders: Time is Running Out to Vote for Extension

Monday, May 10, 2021 - 10:06pm

Proxies previously submitted in respect of the Special Meeting will be voted at the reconvened meeting unless properly revoked.

Key Points: 
  • Proxies previously submitted in respect of the Special Meeting will be voted at the reconvened meeting unless properly revoked.
  • Please note that if your shares are held at a brokerage firm or bank, your broker will not vote your shares for you.
  • Momentus has in-place service agreements with private satellite companies, and research organizations.\nIn connection with the Special Meeting, Stable Road has filed with the Securities and Exchange Commission (\xe2\x80\x9cSEC\xe2\x80\x9d) and sent to its stockholders a definitive proxy statement.
  • The definitive proxy statement has been mailed to Stable Road\xe2\x80\x99s stockholders as of the record date for the Special Meeting.

April AMK Report

Monday, May 10, 2021 - 9:15pm

b'This monthly data is being provided on a supplemental basis and should not be taken as a substitute for the Company\xe2\x80\x99s financial statements filed with the Securities and Exchange Commission as part of the Company\xe2\x80\x99s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021.

Key Points: 
  • b'This monthly data is being provided on a supplemental basis and should not be taken as a substitute for the Company\xe2\x80\x99s financial statements filed with the Securities and Exchange Commission as part of the Company\xe2\x80\x99s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021.
  • AssetMark undertakes no obligation to publicly update or review previously reported monthly data.
  • Any updates to previously reported monthly data will be reflected in the historical data that can be found on the Investor Relations page of the Company\xe2\x80\x99s corporate website at ir.assetmark.com .
  • AssetMark reserves the right to discontinue the availability of the data in this monthly report.

Matterport Accelerates Past Five Million Spaces Under Management

Monday, May 10, 2021 - 2:10pm

Neither Gores nor Matterport gives any assurance that either Gores or Matterport will achieve its expectations.\nIn connection with the proposed business combination, Gores has filed a registration statement on Form S-4 that includes a proxy statement of Gores, an information statement of Matterport and a prospectus of Gores.

Key Points: 
  • Neither Gores nor Matterport gives any assurance that either Gores or Matterport will achieve its expectations.\nIn connection with the proposed business combination, Gores has filed a registration statement on Form S-4 that includes a proxy statement of Gores, an information statement of Matterport and a prospectus of Gores.
  • Gores may also file other documents regarding the proposed business combination with the SEC.
  • Information about Gores\' directors and executive officers and their ownership of Gores\' securities is set forth in Gores\' filings with the SEC.
  • You may obtain free copies of these documents as described in the preceding paragraph.\nThis document relates to a proposed business combination between Gores and Matterport.

Adverum Issues Statement Regarding Upcoming Annual Meeting of Stockholders

Monday, May 10, 2021 - 1:15pm

Adverum, its directors and certain of its executive officers and employees will be participants in the solicitation of proxies from stockholders in respect of the 2021 Annual Meeting.

Key Points: 
  • Adverum, its directors and certain of its executive officers and employees will be participants in the solicitation of proxies from stockholders in respect of the 2021 Annual Meeting.
  • Information regarding the names of Adverum\xe2\x80\x99s directors, executive officers and employees and their respective interests in Adverum by security holdings or otherwise is set forth in the Proxy Statement.
  • Details concerning the nominees of Adverum\xe2\x80\x99s Board of Directors for election at the 2021 Annual Meeting are included in the Proxy Statement.
  • Investors and stockholders can obtain a copy of the Proxy Statement and other relevant documents filed by Adverum free of charge from the SEC\xe2\x80\x99s website, www.sec.gov.

Neovasc Announces First Patient Enrollment in COSIMA Trial

Monday, May 10, 2021 - 2:05pm

b'Certain statements in this news release contain forward-looking statements within the meaning of the U.S.

Key Points: 
  • b'Certain statements in this news release contain forward-looking statements within the meaning of the U.S.
  • Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact.
  • When used herein, the words "expect", "anticipate", "estimate", "may", "will", "should", "intend," "believe", and similar expressions, are intended to\xc2\xa0identify forward-looking statements.
  • The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with securities regulators, whether as a result of new information, future events or otherwise, except as required by law.\n'

Janus International S-4 Registration Statement Related to Business Combination with Juniper Industrial Holdings Declared Effective by SEC

Monday, May 10, 2021 - 1:10pm

The board of directors of Juniper and Janus, have unanimously approved the Business Combination.\n"We are pleased to reach this critical milestone in our proposed business combination process.

Key Points: 
  • The board of directors of Juniper and Janus, have unanimously approved the Business Combination.\n"We are pleased to reach this critical milestone in our proposed business combination process.
  • Juniper\xe2\x80\x99s shareholders and other interested persons are advised to read the definitive proxy statement/prospectus and other documents filed in connection with the proposed business combination, as these materials will contain important information about Juniper, Janus, Janus Parent and the business combination.
  • Janus Parent has mailed the definitive proxy statement/prospectus and other relevant materials for the proposed business combination to shareholders of Juniper as of a record date to be established for voting on the proposed business combination.
  • In addition, the documents filed by Juniper and Janus Parent may be obtained free of charge from Juniper at www.juniperindustrial.com/investors .